Marilyn Huang, MD, discusses the need for non-chemotherapy options in advanced ovarian cancer, as well as data on the use of neoadjuvant PARP inhibitors for this population in the phase 1 NOW study.
Marilyn Huang, MD, MS
Advertisement
Articles by Marilyn Huang, MD, MS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Pumitamig Plus Chemo Demonstrates Encouraging Efficacy in Frontline NSCLC
2
Iza-Bren Improves Survival in Unresectable, Locally Advanced or Metastatic TNBC
3
Oral Administration Afforded by CDK2 Inhibitors May Ease the Price of Admission in Platinum-Resistant Ovarian Cancer
4
MAIC Shows Improved PFS With Zanubrutinib Over Ibrutinib in Treatment-Naive CLL
5